Letko Brosseau & Associates Inc. Increases Stock Position in Illumina, Inc. $ILMN

Letko Brosseau & Associates Inc. increased its position in Illumina, Inc. (NASDAQ:ILMN) by 0.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 858,993 shares of the life sciences company’s stock after acquiring an additional 4,675 shares during the period. Illumina comprises approximately 1.8% of Letko Brosseau & Associates Inc.’s holdings, making the stock its 16th largest position. Letko Brosseau & Associates Inc. owned approximately 0.56% of Illumina worth $112,666,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Capital World Investors grew its position in Illumina by 0.6% in the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after purchasing an additional 124,323 shares during the period. State Street Corp grew its position in Illumina by 6.8% in the 3rd quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock worth $569,800,000 after purchasing an additional 382,520 shares during the period. AQR Capital Management LLC grew its position in Illumina by 3.1% in the 3rd quarter. AQR Capital Management LLC now owns 3,398,027 shares of the life sciences company’s stock worth $315,915,000 after purchasing an additional 102,147 shares during the period. Geode Capital Management LLC grew its position in Illumina by 4.8% in the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock worth $375,260,000 after purchasing an additional 130,139 shares during the period. Finally, Bank of America Corp DE grew its position in Illumina by 1.9% in the 2nd quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock worth $184,222,000 after purchasing an additional 35,167 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. Canaccord Genuity Group cut their target price on shares of Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a research report on Friday, May 1st. Barclays lifted their target price on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research report on Friday, May 1st. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Finally, Royal Bank Of Canada assumed coverage on shares of Illumina in a research report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 target price for the company. Seven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and an average price target of $138.38.

Illumina Trading Up 1.3%

NASDAQ:ILMN opened at $160.03 on Wednesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The firm has a market capitalization of $24.21 billion, a price-to-earnings ratio of 29.10, a price-to-earnings-growth ratio of 2.96 and a beta of 1.50. Illumina, Inc. has a one year low of $85.00 and a one year high of $177.22. The business has a fifty day moving average price of $139.27 and a 200-day moving average price of $134.20.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.Illumina’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts forecast that Illumina, Inc. will post 5.2 EPS for the current year.

Insider Transactions at Illumina

In other news, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. This represents a 3.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the sale, the director owned 2,830,452 shares of the company’s stock, valued at $463,146,860.76. This trade represents a 7.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 1,003,154 shares of company stock worth $155,600,208 over the last three months. 2.90% of the stock is currently owned by insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.